Abstract
The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation of both direct pro-fibrotic pathways and matrix metalloproteinases (MMPs) that enhance collagenase activity. Reactive fibrosis, i.e. deposition of ECM materials remote from the region of the MI is clearly detrimental to ventricular function and contributory to adverse outcomes post- MI. Therefore, reversal of this process represents an important therapeutic target in post-MI management and treatment of established heart failure. A number of existing agents exert their beneficial effects in part via reductions in ECM deposition. Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression.
Keywords: fibrosis, remodelling, renin-angiotensin, endothelin, transforming growth factor, collagen
Current Pharmaceutical Design
Title: Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Volume: 11 Issue: 4
Author(s): Fiona See, Andrew Kompa, Jennifer Martin, Dion A. Lewis and Henry Krum
Affiliation:
Keywords: fibrosis, remodelling, renin-angiotensin, endothelin, transforming growth factor, collagen
Abstract: The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation of both direct pro-fibrotic pathways and matrix metalloproteinases (MMPs) that enhance collagenase activity. Reactive fibrosis, i.e. deposition of ECM materials remote from the region of the MI is clearly detrimental to ventricular function and contributory to adverse outcomes post- MI. Therefore, reversal of this process represents an important therapeutic target in post-MI management and treatment of established heart failure. A number of existing agents exert their beneficial effects in part via reductions in ECM deposition. Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression.
Export Options
About this article
Cite this article as:
See Fiona, Kompa Andrew, Martin Jennifer, Lewis A. Dion and Krum Henry, Fibrosis as a Therapeutic Target Post-Myocardial Infarction, Current Pharmaceutical Design 2005; 11 (4) . https://dx.doi.org/10.2174/1381612053382098
DOI https://dx.doi.org/10.2174/1381612053382098 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pluripotent Stem Cells for Gene Therapy of Degenerative Muscle Diseases
Current Gene Therapy Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Insulin Therapy for Improving Cardiac Surgical Outcomes
Current Drug Targets The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews GHB Pharmacology and Toxicology: Acute Intoxication, Concentrations in Blood and Urine in Forensic Cases and Treatment of the Withdrawal Syndrome
Current Neuropharmacology Neuronal Death and Survival Under Oxidative Stress in Alzheimer and Parkinson Diseases
CNS & Neurological Disorders - Drug Targets Combination Therapy of Inhaled Corticosteroids and Long-Acting β2- Adrenergics In Management of Patients with Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Design The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Association Between Anemia and Dementia: A Nationwide, Populationbased Cohort Study in Taiwan
Current Alzheimer Research Myocardial Perfusion SPECT Imaging in Patients after Percutaneous Coronary Intervention
Current Cardiology Reviews The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age
Current Neuropharmacology Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Clinical Application of Tissue Doppler Imaging in Coronary Artery Diseases and Heart Failure
Recent Patents on Medical Imaging Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design